Abstract
Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult Tcell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.
Keywords: HTLV-1, protease, reverse transcriptase, integrase, envelope glycoproteins, Tax, HBZ, antiretroviral therapies
Infectious Disorders - Drug Targets
Title: Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Volume: 9 Issue: 2
Author(s): Peter Boross, Peter Bagossi, Irene T. Weber and Jozsef Tozser
Affiliation:
Keywords: HTLV-1, protease, reverse transcriptase, integrase, envelope glycoproteins, Tax, HBZ, antiretroviral therapies
Abstract: Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult Tcell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.
Export Options
About this article
Cite this article as:
Boross Peter, Bagossi Peter, Weber T. Irene and Tozser Jozsef, Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection, Infectious Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187152609787847686
DOI https://dx.doi.org/10.2174/187152609787847686 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA Regulation of Embryonic Stem Cell Pluripotency and Differentiation
Current Stem Cell Research & Therapy Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued) Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Drug Delivery Systems for Photodynamic Therapy
Recent Patents on Drug Delivery & Formulation Minimally Invasive Approach to Endometrial Cancer: Robotics and Laparoscopy
Current Women`s Health Reviews Probiotics in Female Reproductive Health: Paradigms, Prospects and Challenges
Current Women`s Health Reviews Quality Survival with Advanced Cervical Cancer
Current Women`s Health Reviews Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Are Bacteriocins Underexploited? NOVEL Applications for OLD Antimicrobials
Current Pharmaceutical Biotechnology Surgical Staging for Cervical Cancer
Current Women`s Health Reviews Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis in Diabetes and Cancer
Infectious Disorders - Drug Targets PCR Detection and Sequencing of <i>Trichomonas vaginalis</i> in Women with Suspected Vaginitis in Southwestern Iran
Infectious Disorders - Drug Targets Treatment Related Morbidity in Cervical Cancer
Current Women`s Health Reviews Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology